Nurix Therapeutics Q2 Loss Narrows, Revenue Surges Premarket

Nurix Therapeutics reported a narrower Q2 loss and revenue more than tripled, leading to a surge in shares premarket. The company is focused on developing targeted protein degradation medicines for cancer and inflammatory diseases. Its clinical-stage pipeline includes NX-5948, NX-2127, and NX-1607, while its preclinical pipeline consists of degraders and degrader antibody conjugates.

San Francisco, CA — Nurix Therapeutics, Inc. (NRIX) has reported robust financial and clinical results for the second quarter of 2025, leading to a significant surge in its stock price premarket. The biopharmaceutical company, focused on targeted protein degradation therapies, experienced a substantial increase in revenue, reaching $44.1 million, a 265.3% year-over-year growth from $12.1 million [1].

Despite increased research and development expenditures, Nurix managed to narrow its net loss to $43.5 million, or $0.52 per share, compared to $44.5 million, or $0.71 per share, in the same quarter of the previous year [1]. The company's cash and marketable securities stood at $485.8 million at the end of the fiscal quarter, providing a substantial runway for ongoing and future clinical endeavors [1].

In clinical updates, Nurix presented promising Phase 1 data for its drug candidate bexobrutideg (NX-5948), which exhibited an 80.9% objective response rate in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) [1]. The treatment demonstrated a favorable safety profile, with no instances of atrial fibrillation or systemic fungal infections, issues commonly associated with similar treatments, indicating its potential for further pivotal trials.

The company's strategic collaborations also marked significant progress. Nurix secured a $15 million payment from Sanofi for extending its license for the STAT6 program, a collaboration that has now surpassed $127 million in total payments [1]. Additionally, the U.S. Food and Drug Administration (FDA) cleared the IND application for GS-6791/NX-0479, enabling partner Gilead to initiate phase 1 trials, broadening Nurix's therapeutic reach in the field of inflammation [1].

Nurix's clinical-stage pipeline includes NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases [2].

These advancements illustrate Nurix's leading position in the evolving landscape of degrader-based therapeutics. The company's strategic collaboration with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization of multiple drug candidates further underscores its commitment to innovation and market penetration [2].

References:
[1] https://www.gurufocus.com/news/2967823/nurix-therapeutics-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update-nrix-stock-news
[2] https://finance.yahoo.com/quote/NRIX/